0001127602-22-028239.txt : 20221223 0001127602-22-028239.hdr.sgml : 20221223 20221223161535 ACCESSION NUMBER: 0001127602-22-028239 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220425 FILED AS OF DATE: 20221223 DATE AS OF CHANGE: 20221223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eisele Jeffrey CENTRAL INDEX KEY: 0001827326 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 221485554 MAIL ADDRESS: STREET 1: APELLIS PHARMACEUTICALS, INC. STREET 2: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-04-25 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001827326 Eisele Jeffrey C/O APELLIS PHARMACEUTICALS, INC. WALTHAM MA 02451 1 Exec VP, Program Team Lead Common Stock 2022-04-25 4 J 0 1250 0 D 31739 D Common Stock 2022-12-22 4 F 0 89 51.68 D 31650 D This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met. This represents shares used to cover tax withholding on a Restricted Stock Unit release. /s/ David Watson, attorney-in-fact for Jeffrey Eisele 2022-12-23